Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nuc-1031 and carboplatin in recurrent ovarian cancer
NCT02303912Phase 1Completed
- Sponsor
- Imperial College Healthcare NHS Trust
- Start
- Nov 2014
- Primary completion
- Jan 2017
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of gemcitabine monophosphate ProTide in ovarian cancer, sponsored by Imperial College Healthcare NHS Trust. Primary endpoint: Recommended Phase II Dose at 1 year. Started Nov 2014; status: completed.
02
Drugs
gemcitabine monophosphate ProTide
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02303912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303912.